Last reviewed · How we verify
NCT06923657
PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy
NA trial testing PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy in Prostate Cancer Screening in 230 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | First Affiliated Hospital of Fujian Medical University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 230 |
| Start date | 7 May 2025 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy
- TRUS guided transperineal saturation biopsy
Conditions studied
- Prostate Cancer Screening — all drugs for Prostate Cancer Screening →
- PSMA-PET — all drugs for PSMA-PET →
Sponsor
First Affiliated Hospital of Fujian Medical University
Who can join
Adults 30 to 85, male only, with Prostate Cancer Screening or PSMA-PET. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal is to provide more accurate diagnostic tools and optimized diagnostic workflows for clinically suspected prostate cancer patients with prior negative biopsies, improving early detection rates for csPCa and reducing missed diagnoses.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06923657
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer Screening
Currently open trials in the same condition.
- NCT06626022 — Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging. · Phase 3 · recruiting
- NCT05608694 — MRI Screening in Men at High Risk of Developing Prostate Cancer · NA · recruiting
Other First Affiliated Hospital of Fujian Medical University trials
Trials by the same sponsor.
- NCT07513844 — Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease · NA · not yet recruiting
- NCT07337772 — Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty · NA · recruiting
- NCT07369401 — Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory · NA · not yet recruiting
- NCT07378358 — Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study · recruiting
- NCT07363382 — The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06923657 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Fujian Medical University
- Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06923657.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing